drugset / Trial / NCT01773798
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
RandomizedCrossoverDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of insulin degludec/insulin aspart 15 in subjects with type 1 diabetes.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin aspart | Protein / enzyme biologic | 0.075 iu/kg | Subcutaneous |
| Subject | insulin degludec | Protein / enzyme biologic | 0.425 iu/kg | Subcutaneous |
| Subject | insulin degludec | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
| Subject | insulin degludec/insulin aspart | Unknown | 0.5 iu/kg | Subcutaneous |